Company intelligence / Profile preview

Seakura

Caesarea, Haifa District, Israelseakura.com ↗

Ownership: Private
Development stage: Other

Overview

Seakura has commercialized its proprietary land-based macroalgae cultivation platform. Its products include organic seaweeds rich in protein, minerals, fibers, vitamins, carotenoids, and antioxidants. The company emphasizes sustainability by using its technology to clean brine nitrates from desalination plants while producing high-quality biomass for nutraceuticals and other uses. No clinical trial results apply.

Therapeutic areas: Metabolic Disorders
Modalities: Nutritional supplement (from seaweed)Functional food ingredient (seaweed-based)
Industry: Food & Nutrition

Partnerships

University of Maryland (Prof. Yoni Zohar)Dr. Michael Friedlander

Beyond the preview

Go deeper on Seakura.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seakura.

Explore the full profile